ADAP Advocacy Releases New White Paper Calling for 340B Drug Pricing Reform

GTTP

The 340B Program has shifted focus from patient advocacy to institutional provider financial interests.
Increased transparency is necessary to align the program with its original legislative purpose.
Rising patient costs suggest that the current 340B model is failing the uninsured and underinsured.
ADAP Advocacy calls for robust accountability guardrails to ensure efficiency and equitable access to care.

Impact - Why it Matters

This white paper is significant because it challenges the status quo of a massive federal program, shifting the focus back to patient-centric outcomes. By demanding transparency, ADAP Advocacy aims to curb systemic inefficiencies, ensuring that the 340B program serves its intended purpose of expanding equitable care for vulnerable populations.

Summary

ADAP Advocacy has officially published a retrospective white paper, 340B Program: The Glue That Should Hold Our Healthcare System Together, which critically examines the evolution and current state of the federal 340B Drug Pricing Program. As the second-largest federal prescription drug initiative in the United States, the program faces growing scrutiny for drifting away from its legislative intent. The organization argues that the program currently prioritizes provider interests over the urgent needs of the vulnerable patients it was originally designed to support.

CEO Brandon M. Macsata emphasizes that as transparency becomes a standard expectation across the healthcare industry, the 340B program must also face increased accountability. The white paper highlights a significant disconnect between the program's massive financial growth and its actual impact on patient affordability. ADAP Advocacy contends that without rigorous guardrails, the program fails to adequately serve the uninsured and underinsured populations who rely on it for life-saving access to care.

The report advocates for a comprehensive shift toward greater transparency to ensure the 340B program fulfills its primary mission of improving healthcare access for low-income individuals. By questioning why rising costs persist despite the program's scale, the organization pushes for structural reforms that prioritize patient outcomes over institutional financial gain. Interested stakeholders can access the full report on the official ADAP Advocacy website to review the proposed policy recommendations.

ADAP Advocacy Releases New White Paper Calling for 340B Drug Pricing Reform

GTTP

The 340B Program has shifted focus from patient advocacy to institutional provider financial interests.
Increased transparency is necessary to align the program with its original legislative purpose.
Rising patient costs suggest that the current 340B model is failing the uninsured and underinsured.
ADAP Advocacy calls for robust accountability guardrails to ensure efficiency and equitable access to care.